Background: Morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) are the two most important metabolites of morphine. Both are pharmacologically active, however, with different effects. M-6-G has been demonstrated capable of inducing anti-nociception and sedation, and M-3-G may induce behavioural excitation and possibly antagonise anti-nociception. Their impact on pharmacodynamics in patients in long-term treatment with oral morphine remains to be settled.
Methods: Forty-two cancer patients treated with oral sustained-release (SR) morphine were assessed for pain, sedation and other side effects related to morphine treatment. Blood samples were analysed for morphine, M-3-G and M-6-G by high-performance liquid chromatography (HPLC).
Results: Significant correlations were found between the daily dose of SR morphine and plasma morphine (M) (r=0.535, P<0.001), plasma M-6-G (r =0.868, P<0.001) and plasma M-3-G (r =0.865, P<0.001). There was no relationship between plasma morphine, M-6-G, M-6-G/M and pain and sedation scores. Seventy-nine percent of the patients suffered from dryness of the mouth, which was the most frequent side effect observed. Patients in this group had higher plasma morphine and M-6-G concentrations than patients who did not suffer from this side effect.
Conclusion: The plasma concentrations of morphine and its metabolites, M-3-G and M-6-G, are significantly correlated to the daily dose of SR morphine. Although M-6-G has analgesic properties, no associations were found between pain and plasma morphine and morphine metabolites. This may be due to the multitudinous factors affecting the dose effect relationship. Patients with dryness of the mouth had higher concentrations of morphine and M-6-G than patients without this side effect.
Vater M, Smith G, Aherne GW, Aitkenhead AR. Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers. Br J Anaesth1984; 56: 821–827.
2.
Sa Èwe J, DahlstroÈm B, Paalzow L, Rane A. Morphine kinetics in cancer patients. Clin Pharmacol Ther1981; 30: 629–635.
3.
Wolff T, Samuelsson H, Hedner T. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain1995; 62: 147–154.
4.
Faura CC, Moore A, Horga JF, Hand CW, McQuay HJ. Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. J Pain Symptom Manage1996; 11: 95–102.
5.
Poulain P, Hoskin PJ, Hanks GW, A-Omar O, Walker VA, Johnston A, Turner P, Aherne GW. Relative bioavailability of controlled release morphine tablets (MST Continus) in cancer patients. Br J Anaesth1988; 61: 569–574.
6.
Van Dongen RTM, Crul BJP, Koopman-Kimenai PM, Vree TB. Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine. Br J Clin Pharmacol1994; 38: 271–273.
7.
Sa Èwe J, Svensson JO, Rane A. Morphine metabolism in cancer patients on increasing oral doses – no evidence for autoinduction or dose-dependence. Br J Clin Pharmacol1983; 16: 85–93.
8.
McQuay HJ, Carroll D, Faura CC, Gavaghan DJ, Hand CW, Moore RA. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther1990; 48: 236–244.
9.
Hanna MH, Peat SJ, Woodham M, Knibb A, Fung C. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J Anaesth1990; 64: 547–550.
10.
Grace D, Fee JPH. A comparison of intrathecal morphine-6-glucuronide and intrathecal morphine sulfate as analgesics for total hip replacement. Anesth Analg1996; 83: 1055–1059.
11.
Morley JS, Miles JB, Wells JC, Bowsher D. Paradoxical pain. Lancet1992; 340: 1045–1045.
12.
Sjùgren P, Thu Ènedborg LP, Christrup L, Hansen SH, Franks J. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration?Acta Anaesthesiol Scand1998; 42: 1070–1075.
13.
Gong QL, Hedner J, BjoÈrkman R, Hedner T. Morphine-3-glucuronide may functionally antagonize morphine-6- glucuronide induced antinociception and ventilatory depression in the rat. Pain1992; 48: 249–255.
14.
Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide: a potent antagonist of morphine analgesia. Life Sci1990; 47: 579–585.
15.
Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky Performance Status. Cancer1980; 45: 2220–2224.
16.
Orr ST, Aisner J. Performance status assessment among oncology patients: a review. Cancer Treat Rev1986; 70: 1423–1429.
17.
Sa Èwe J. Morphine and its 3-and 6-glucuronides in plasma and urine during chronic oral administration in cancer patients. In: Foley KM, Inturrisi CE eds. Advances in pain research and therapy. New York: Raven Press, 1986: 45– 55.
18.
Portenoy RK, Khan E, Layman M, Lapin J, Malkin MG, Foley KM, Thaler HT, Cerbone DJ, Inturrisi CE. Chronic morphine therapy for cancer pain: plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations. Neurology1991; 41: 1457–1461.
19.
Hoskin PJ, Hanks GW, Heron CW, Aherne GW, Chapman D. M6G and its analgesic action in chronic use. Letter. Clin J Pain1989; 5: 199–200.
20.
Peat S, Hanna M, Durcan T, Fung M. Morphine-6-glucuronide in postoperative pain. Book of Abstracts, – 9th World Congress on Pain, Vienna, Austria, 1999, p. 335–335.
21.
Osborne R, Thompson P, Joel S, Trew D, Patel N, Slevin M. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol1992; 34: 130–138.
22.
Thompson PI, Joel SP, John L, Wedzicha JA, Maclean M, Slevin ML. Respiratory depression following morphine and morphine-6-glucuronide in normal subjects. Br J Clin Pharmacol1995; 40: 145–152.
23.
Portenoy RK, Thaler HT, Inturrisi CE, Friedlander-Klar H, Foley KM. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther1992; 51: 422–431.
24.
Klepstad P, Kaasa S, Borchgrevink PC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol2000; 55: 713–719.
25.
Wolff T, Samuelsson H, Hedner T. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients. Pain1996; 68: 209–216.
26.
Somogyi AA, Nation RL, Olweny C, Tsirgiotis P, van Crugten J, Milne RW, Cleary JF, Danz C, Bochner F. Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine. Clin Pharmacokinet1993; 24: 413–420.
27.
Samuelsson H, Hedner T, Venn R, Michalkiewicz A. CSF and plasma concentrations of morphine and morphine glucuronides in cancer patients receiving epidural morphine. Pain1993; 52: 179–185.
28.
Tiseo PJ, Thaler HT, Lapin J, Inturrisi CE, Portenoy RK, Foley KM. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain1995; 61: 47–54.
29.
Ashby M, Fleming B, Wood M, Somogyi A. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice patients. J Pain Symptom Manage1997; 14: 157–167.
30.
Christrup LL, Sjùgren P, Jensen N-H, Banning A-M, Elbñk K, Ersbùll AK. Steady-state kinetics and dynamics of morphine in cancer patients. Is sedation related to the absorption rate of morphine?J Pain Symptom Manage1999; 18: 164–173.
31.
White ID, Hoskin PJ, Hanks GW, Bliss JM. Morphine and dryness of the mouth. BMJ1989; 298: 1222–1223.
32.
Ventafridda V, Tamburini M, Caraceni A, de Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer1987; 59: 850–856.
33.
Westerling D, Persson C, HoÈglund P. Plasma concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers: relationship to nonanalgesic actions. Ther Drug Monit1995; 17: 287–301.
34.
Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M. Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects. Anesth Analg1987; 66: 293–298.
35.
Hasselstro Èm J, Eriksson S, Persson A, Rane A, Svensson JO, Sa Èwe J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol1990; 29: 289–297.
36.
Patwardhan RV, Johnson RF, Hoyumpa A, Sheehan JJ, Desmond PV, Wilkinson GR, Branch RA, Schenker S. Normal metabolism of morphine in cirrhosis. Gastroenterology1981; 81: 1006–1011.
